Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gallium-68 relitegatide brexetan
- Development stage
- Unknown
- Lead developer
- Radiopharm Theranostics, Ltd
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
Gallium-68 trivehexin (gallium-68 relitegatide brexetan; RAD 301) is an investigational, peptide-based radiopharmaceutical diagnostic imaging agent designed for positron emission tomography (PET) imaging. It consists of a C3-symmetrical trimeric peptide conjugate (trivehexin) labeled with the positron-emitting radioisotope gallium-68. The peptide moiety, relitegatide, selectively targets the active conformation of integrin alpha-V beta-6 (αvβ6), a cell-surface receptor that is minimally expressed in healthy tissues but highly overexpressed in various epithelial malignancies, particularly pancreatic ductal adenocarcinoma (PDAC) and head and neck squamous cell carcinoma (HNSCC). Originally developed by TRIMT GmbH (later acquired by ABX), the agent is licensed to Radiopharm Theranostics for development in the US, Australia, China, Hong Kong, and Japan. It is currently being evaluated in Phase 1 and Phase 2 clinical trials for the detection and staging of pancreatic cancer, head and neck cancer, and other solid tumors.
- Brand names
- Trivehexin
- Other names
- 68Ga-Trivehexin68Ga-relitegatide brexetangallium Ga-68 relitegatide brexetangallium-68 trivehexingallium68 trivehexingallium 68 trivehexin
02
Targets
αVβ6 (Integrin αVβ6)
Beyond the preview
Go deeper on gallium-68 relitegatide brexetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gallium-68 relitegatide brexetan.